Suzuken Co., Ltd.
SZUKF
Other OTC30.30
USD
- -
- -
ISIN
JP3398000004
Return %
Stock
S&P500
1Y
- -
15.98
3Y
25.94
62.25
5Y
4.16
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Shigeru Asano
- Full Time Employees
- 12,717
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- 8 Higashi Kataha-machi Nagoya AI Japan 461-8701
- IPO Date
- Sep 10, 2013
- Website
- suzuken.co.jp
- Similar Companies
- Business
- Suzuken Co., Ltd. Suzuken Co., Ltd. engages primarily in pharmaceutical distribution and related healthcare services in Japan. The company operates through four main segments: pharmaceutical wholesale, which involves marketing ethical pharmaceuticals, diagnostic reagents, medical equipment, supplies, and medical foods to medical institutions and insurance pharmacies; pharmaceutical manufacturing, which focuses on research, development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic reagents, particularly in areas such as diabetes and kidney diseases; insurance pharmacy, which provides dispensing operations and medication instruction for in-home patients based on prescriptions from medical institutions; and healthcare-related services, which encompass manufacturer support including transportation of medicines and comprehensive distribution for rare diseases, nursing care services, manufacturing and sales of physiological examination equipment such as electrocardiographic monitors, blood pressure monitors, and stethoscopes under the Kenz brand, publication and PR activities in medical care and health, insurance agency business, remote image diagnostic support, pharmaceutical logistics, and sales of medical books and fixtures. Suzuken Co., Ltd. maintains an extensive national network with approximately 18 distribution centers and over 11 manufacturer distribution centers, six transportation terminals, and serves more than 22,000 healthcare facilities across Japan, targeting medical institutions, pharmacies, and patients with a portfolio exceeding 80,000 pharmaceutical and medical products. Founded on November 13, 1932, by Kenzo Suzuki and headquartered at 8 Higashi Kataha-machi, Higashi-ku, Nagoya, Aichi 461-8701, Japan, the company employs 12,923 consolidated staff as of March 2025 and lists on the Prime Markets of the Tokyo, Nagoya, and Sapporo Stock Exchanges under ticker 9987. In recent developments, Suzuken Co., Ltd. launches operations at the Greater Tokyo Distribution Center in April 2024 through its collaboration with Bushu Pharmaceuticals Ltd. initiated in April 2021, featuring on-site contract manufacturing, inspection, labeling, packaging, and storage services to support foreign pharmaceutical companies entering Japan; establishes the J-ENTRY Consortium in May 2024 with Bushu Pharmaceuticals and EPS Holdings to provide one-stop support for overseas firms, covering specialty drug development, marketing approval applications, manufacturing, sales, marketing, and distribution on a contingency fee basis to reduce drug loss and financial risks; expands the Cubixx System for temperature-controlled logistics and total traceability, now in use at over 400 facilities including new versions for home use, large-capacity, and room temperature storage since 2021; and introduces VIXELL cooling box-based home delivery services in 2022 for products like Byclot Combination Intravenous Injection for hemophilia, partnering with GENie for specialized drug delivery. These initiatives advance Suzuken Co., Ltd.'s transformation into a health creation enterprise, enhancing specialty drug distribution for rare diseases and cell/gene therapies, global logistics via partnerships like World Courier since 2018, and sustainable supply chain efficiency while pursuing ESG-focused growth.